Daiichi Sankyo (OTCMKTS:DSNKY) Shares Up 5.2% – What’s Next?

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) traded up 5.2% during mid-day trading on Monday . The company traded as high as $18.43 and last traded at $18.40. 3,199 shares changed hands during trading, a decline of 99% from the average session volume of 343,306 shares. The stock had previously closed at $17.49.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DSNKY. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Daiichi Sankyo Stock Up 1.7%

The business’s 50 day moving average is $17.43 and its 200 day moving average is $17.28. The company has a market capitalization of $34.28 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 2.48 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Sell-side analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.